Evidence map›Paper›PMID 40688071›Full record

ArticleFrontiers in immunology2025

The TNFα-binding domain of the therapeutic antibody adalimumab elicits CD4 T-cell responses in rheumatoid arthritis patients.

Mateusz Makuch, Josine van Beek, Carla A Wijbrandts, Marja Aalbers, Philippe Stas, Alexander B Meijer, Anja Ten Brinke, Theo Rispens, Paul Peter Tak, Gertjan Wolbink and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mateusz MakuchSanquin Research, Department of Immunopathology, and Landsteiner Laboratory, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam, Netherlands.
Josine van BeekSanquin Research, Department of Immunopathology, and Landsteiner Laboratory, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam, Netherlands.
Carla A WijbrandtsDepartment of Rheumatology, Reade, Amsterdam, Netherlands.
Marja AalbersSanquin Research, Department of Immunopathology, and Landsteiner Laboratory, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam, Netherlands.
Philippe StasImmunXperts, Gosselies, Belgium.
Alexander B MeijerDepartment of Plasma Proteins, Van Creveld Laboratory of University Medical Center (UMC) Utrecht and Sanquin Research, Amsterdam, Netherlands.
Anja Ten BrinkeSanquin Research, Department of Immunopathology, and Landsteiner Laboratory, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam, Netherlands.
Theo RispensSanquin Research, Department of Immunopathology, and Landsteiner Laboratory, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam, Netherlands.
Paul Peter TakDepartment of Rheumatology and Clinical Immunology, Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands.
Gertjan WolbinkSanquin Research, Department of Immunopathology, and Landsteiner Laboratory, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam, Netherlands.
Janine SchuurmanGenmab, Utrecht, Netherlands.
Paul W H I ParrenGenmab, Utrecht, Netherlands.
S Marieke van HamSanquin Research, Department of Immunopathology, and Landsteiner Laboratory, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment efficacy of patients receiving anti-TNF antibodies is limited by the formation of anti-drug antibodies. These are observed in most adalimumab-treated rheumatoid arthritis patients, despite the adjuvant-free and human sequence-derived nature of the antibody. The class switched phenotype and high affinity of these antibodies suggest CD4 T-cell involvement in their formation. In this study, we investigated the potential epitopes in the functional domain of adalimumab and assessed their actual HLA II presentation and induction of CD4 T-cell responses in exposed patients. The binding strength of overlapping adalimumab-derived peptides to 27 DR and 14 DQ HLA alleles was predicted

Indexed as

AdalimumabAntirheumatic AgentsArthritis, RheumatoidCD4-Positive T-LymphocytesTumor Necrosis Factor-alphaAdultAgedAntigen PresentationEpitopes, T-LymphocyteFemaleHLA-DR AntigensHumansMaleMiddle AgedProtein BindingAdalimumabAntirheumatic AgentsEpitopes, T-LymphocyteHLA-DR AntigensTumor Necrosis Factor-alphaanti-drug antibodiesanti-TNF therapyCD4 T cellsimmunogenicityrheumatoid arthritis

Identifiers

PMID40688071
PMCPMC12273444

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.